OncoDxRx Focused on Building One-Of-A-Kind Liquid Biopsy Theranostic Capability
OncoDxRx develops one-of-a-kind liquid biopsy technologies to solve huge market demands.
- (1888PressRelease) January 05, 2023 - OncoDxRx, which is using its multiple one-of-a-kind liquid biopsy technologies to speed up precision medicine, is seeking for investment and partnership. The scientists expressed their company with the expertise, knowhow and dynamism of stereotypical high-tech startup.
According to the company, PGA (Patient-derived Gene expression-informed Anti-cancer drug efficacy) technology is the “game changer” because precision medicine currently only benefits 20-30% cancer patients. “PGA, on the other hand, targets this 70-80% population whose biomarker testing are negative, hence completing the puzzle and benefiting the entire cancer population,” the company said.
OncoDxRx also is now developing multi-cancer early detection (MCED) and minimal residual disease (MRD) tests, both of which leveraging on exclusive cell-free DNA methylation and mRNA profiling technologies with huge market demands worldwide.
The company has remarkably outgrown its current pipelines to cover all stages of cancer from early detection, treatment selection, monitoring, recurrence to therapeutics discovery.
OncoDxRx’s role as a driver of precision medicine is a result of being thinking outside of the box and realization of what patients are truly needed most.
The DNA repair activity measurement is another breakthrough that can be used to quantify DNA repair function, either HRR (homologous recombination repair) or MMR (mismatch repair), in circulation without the labor-intensive, time-consuming and costly sequencing or multimodal testing. According to OncoDxRx, the technology has robust chemistry and benefits from high throughput, automation and quick turnaround.
Unlike OncoDxRx, many biotech and clinical laboratory startups appear to be service companies. “Our business model is making revenue and validating exclusive technologies we can sell as fast as possible, as we don’t have the same possibilities as the big players.” The company noted.
“As reputations die hard, and we’re a small company in a big world—we have to reach out to be seen.” The company concluded.
Follow us on Linkedin: https://www.linkedin.com/company/oncodxrx/?viewasmember=true&original_referer=
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam